Venge P, Dahl R, Håkansson L
Department of Clinical chemistry, University Hospital, Uppsala, Sweden.
J Allergy Clin Immunol. 1987 Nov;80(5):679-88. doi: 10.1016/0091-6749(87)90287-9.
Neutrophil chemotactic activity (NCA) in serum is raised in subjects with asthma after inhalation of an allergen. Two kinds of NCA have been demonstrated, heat-stable and heat-labile. In addition, inhibitory activity is generated after inhalation challenge. In the present study we have investigated the relationship of heat-labile NCA to the development of the late asthmatic reaction (LAR) in 13 subjects with asthma after allergen challenge and the effects of asthma medication on the formation of this activity. Heat-labile NCA peaked 120 to 240 minutes after challenge and demonstrated at this time significant (p less than 0.001) quantitative relationships to the ensuing LAR. The inhalant corticosteroid, budesonide, significantly inhibited (p less than 0.001) the generation of heat-labile NCA and the development of LAR both after a single dose and after 4 weeks of pretreatment. Single-dose disodium cromoglycate pretreatment, initially, slightly enhanced (p less than 0.05) heat-labile NCA but, after 120 minutes, slightly inhibited (p less than 0.05) the activity. Disodium cromoglycate also slightly abrogated the development of LAR. Single-dose pretreatment with the beta 2-agonist, terbutaline, inhibited generation of heat-labile NCA (p less than 0.001) but was without effect on LAR. It is concluded that the generation of heat-labile NCA is related to the development of the LAR and may be of importance for the attraction of inflammatory cells to the lung in the development of the inflammatory reaction probably responsible for LAR. However, the pharmacologic control of heat-labile NCA indicates that the process is multifactorial and not solely dependent on the generation of NCAs detected in serum.
吸入变应原后,哮喘患者血清中的中性粒细胞趋化活性(NCA)会升高。已证实存在两种NCA,即热稳定型和热不稳定型。此外,吸入激发后会产生抑制活性。在本研究中,我们调查了13例哮喘患者变应原激发后热不稳定型NCA与迟发性哮喘反应(LAR)发生之间的关系,以及哮喘药物对该活性形成的影响。热不稳定型NCA在激发后120至240分钟达到峰值,此时与随后的LAR呈现显著(p<0.001)的定量关系。吸入性皮质类固醇布地奈德在单次给药后及预处理4周后,均能显著抑制(p<0.001)热不稳定型NCA的产生以及LAR的发生。单次剂量的色甘酸钠预处理最初会轻微增强(p<0.05)热不稳定型NCA,但在120分钟后会轻微抑制(p<0.05)该活性。色甘酸钠也能轻微减轻LAR的发生。β2激动剂特布他林单次剂量预处理可抑制热不稳定型NCA的产生(p<0.001),但对LAR无影响。结论是,热不稳定型NCA的产生与LAR的发生有关,可能在炎症反应发展过程中对炎症细胞向肺部的募集具有重要意义,而炎症反应可能是LAR的原因。然而,对热不稳定型NCA的药物控制表明该过程是多因素的,并非仅依赖于血清中检测到的NCA的产生。